信立泰(002294.SZ):阿利沙坦酯氨氯地平片獲批臨牀試驗
格隆匯 12 月 24日丨信立泰(002294.SZ)公佈,近日,公司收到國家藥品監督管理局核准簽發的《臨牀試驗批准通知書》,同意“阿利沙坦酯氨氯地平片”按照公司提交的方案開展臨牀試驗。
阿利沙坦酯氨氯地平片(項目代碼:SAL0107)為ARB/CCB類複方製劑,適應症暫定為抗高血壓。該產品上市後,將與公司已上市的1.1類降壓藥信立坦(阿利沙坦酯片)形成戰略協同,擴大信立坦的應用範圍,進一步延長信立坦的產品生命週期,豐富公司心腦血管領域的創新產品管線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.